This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We may also share information about your use of our site with analytics partners. Read about cookies in our Cookie Policy. By clicking “Accept”, you are indicating your consent to our use of cookies and policies.
Founded in 2018, Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs in serious musculoskeletal diseases. With our team's experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need.
